- Home
- EOSE vs PRCT Comparison
EOSE vs PRCT Comparison
Compare EOSE & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EOSE | PRCT |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EOSE | PRCT |
|---|---|---|
| Price | $1.89 | $22.16 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 15 |
| Target Price | $5.84 | ★ $22.75 |
| AVG Volume (30 Days) | ★ 23.9M | 1.3M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | ★ N/A | N/A |
| Revenue | $114,203,000.00 | ★ $308,054,000.00 |
| Revenue This Year | $168.84 | $28.32 |
| Revenue Next Year | $87.03 | $20.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 631.79 | 37.22 |
| 52 Week Low | $1.59 | $16.67 |
| 52 Week High | $19.65 | $38.11 |
Technical Indicators
Market Signals| Indicator | EOSE | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 40.43 | 63.73 |
| Support Level | N/A | $20.22 |
| Resistance Level | $4.45 | $23.32 |
| Average True Range (ATR) | 0.21 | 1.45 |
| MACD | 0.07 | 0.26 |
| Stochastic Oscillator | 35.81 | 70.25 |
Price Performance
Historical ComparisonAbout EOSE Eos Energy Enterprises Inc.
Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial & industrial (C&I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.